Dr Hiley is an Associate Professor with tenure in Radiation Oncology at UCL and a Consultant Clinical Oncologist at UCLH.
He graduated with honours from the University in Manchester in 2005. He has trained in Oncology at many centres of excellence both in the UK and abroad. These include the Christie Hospital, the MD Anderson Cancer Centre (Houston, USA), Kings College (NIHR Clinical Lecturer) and the Royal Marsden (NIHR Clinical Fellow). He completed a PhD at the University of London with the Barts Cancer Institute and a postdoctoral research Fellowship at the Francis Crick Institute and the UCL Cancer Institute.
He became a consultant in 2018 and is clinical lead of the clinical oncology lung team at UCLH, UCLH Lead for Lung Proton Therapy, Deputy Lead of Clinical Trials for the CRUK Lung Cancer Centre of Excellence and NIHR Clinical Research Network Speciality Research Lead Radiotherapy for North London. He heads a research group at the UCL Cancer Institute focused on understanding resistance to radiation therapy.
Dr Hiley specialises in all the non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy and Stereotactic Radiotherapy (SBRT).
He is the principal investigator and national chief investigator for a number of academic and commercial clinical trials in lung cancer. He has published in a number of the world’s leading journals including NEJM, The Lancet, Nature and Cell. He is a member of the expert group which authored the Radiotherapy for Lung Cancer Royal College of Radiologists Consensus Statement.
- Francis Crick Translation Fellow
- Royal College of Radiologist Ross Award
- The Wolfson Foundation Scholarship
- Dreschfield Memorial Scholarship
- Management of locally advanced lung cancer.
- Role of radiotherapy in mesothelioma.
- Immunotherapy for non-small cell lung cancer
- SABR for oligometastatic disease
- Proton therapy for lung cancers
- Understanding resistance to radiotherapy and immunotherapy in NSCLC.
- Proton therapy
Publications & affiliations
- Round, T., L’Esperance, V., Bayly, J., Brain, K., Dallas, L., Edwards, J. G., . . . Navani, N. (2021).COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary. British Journal of Cancer. doi:10.1038/s41416-021-01361-6
- Ding, H., Jimeno, C. V., Ye, H., Lindner, T., Grech-sollars, M., O’callaghan, J., . . . Adeleke, S. (2021).Current applications and future development of magnetic resonance fingerprinting in diagnosis, characterization, and response monitoring in cancer. Cancers, 13 (19). doi:10.3390/cancers13194742
- Punjabi, A., Barrett, E., Cheng, A., Mulla, A., Walls, G., Johnston, D., . . . Evison, M. (2021).Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer. CLINICAL ONCOLOGY, 33 (8), E331-E338. doi:10.1016/j.clon.2021.03.019
- Szmul, A., Chandy, E., Veiga, C., Stavropoulou, A., Jacob, J., Landau, D., . . . McClelland, J. (2021).Radiation Induced Lung Damage Tissue Segmentation and Classification Framework.
- Shen, J., Zhuang, W., Xu, C., Jin, K., Chen, B., Tian, D., . . . Qiao, G. (2021). Surgery or Non-surgical Treatment of <= 8 mm Non-small Cell Lung Cancer: A Population-Based Study. FRONTIERS IN SURGERY, 8, ARTN 632561. doi:10.3389/fsurg.2021.632561